(Press-News.org) WASHINGTON, Aug. 18, 2025 — Acetaminophen is one of the most common painkillers and is found in hundreds of different medications. While safe at recommended doses, acetaminophen overdose is the leading cause of acute liver injury in the U.S. Now, researchers propose that a new molecule has the potential to treat acetaminophen-induced liver injury (AILI) and other inflammatory conditions. They conducted a small-scale mouse trial and found that the new compound decreased AILI-caused liver inflammation and prevented liver damage.
Jannatun Nayem Namme, a graduate student at Virginia Commonwealth University, will present her team’s results at the fall meeting of the American Chemical Society (ACS). ACS Fall 2025 is being held Aug. 17-21; it features about 9,000 presentations on a range of science topics.
Most acetaminophen overdoses are accidental, often due to people unintentionally consuming multiple products containing the painkiller or misinterpreting dosage. After taking a recommended amount of acetaminophen, a person’s liver converts a small percentage of it into a toxic molecule called N-acetyl-p-benzoquinone imine (NAPQI). Normally, the liver can quickly metabolize NAPQI into a non-toxic form. But if a person takes too much acetaminophen, NAPQI builds up and causes irreversible cell damage, leading to liver injury or death. Currently, N-acetylcysteine is the only drug available to treat AILI, and it must be administered within eight hours of overdose.
To develop novel treatments for inflammatory conditions, such as AILI, and neurodegenerative conditions, Namme and her colleagues previously focused on small molecules that reduce the activity of inflammation-causing proteins, known as inflammasomes. Inflammasomes are also involved in pyroptosis, a type of cellular death associated with AILI. While developing inflammasome inhibitors, the researchers noticed that some of the compounds they created could target a specific inflammatory protein called gasdermin D (GSDMD). GSDMD is involved in pyroptosis.
Namme and the team synthesized several different GSDMD-inhibiting compounds and tested them for their ability to bind to GSDMD. They discovered that one small molecule, which they labeled YM81, selectively binds to and inhibits GSDMD from initiating pyroptosis.
Next, the researchers treated five mice with AILI using YM81 and compared them to 10 mice given a placebo. They monitored the extent of liver damage in the animals 17 hours after the acetaminophen overdose. Compared to the placebo group, mice treated with YM81 had significantly lower levels of alanine transaminase and aspartate transaminase, two liver injury biomarkers. These results indicate that the YM81 treatment helped decrease liver inflammation by inhibiting GSDMD.
Shijun Zhang, the study’s principal investigator, says that YM81 is in the early stages of drug development. “In the future, we will focus on optimizing YM81 to increase its potency, safety and stability, in addition to exploring its therapeutic potential in additional animal models,” he says.
Namme adds that GSDMD inhibitors like YM81 have the potential to treat other inflammatory conditions. “GSDMD is a common protein involved in multiple inflammatory and neurodegenerative diseases, such as arthritis, sepsis and gout,” she says. “Targeting GSDMD could offer a therapeutic strategy to reduce the inflammation and damage from multiple diseases and causes.”
The research was partially funded by the National Institute of Aging of the U.S. National Institutes of Health.
Visit the ACS Fall 2025 program to learn more about this presentation, “Development of a novel GSDMD inhibitor for the treatment of acetaminophen-induced liver injury,” and other science presentations.
###
The American Chemical Society (ACS) is a nonprofit organization founded in 1876 and chartered by the U.S. Congress. ACS is committed to improving all lives through the transforming power of chemistry. Its mission is to advance scientific knowledge, empower a global community and champion scientific integrity, and its vision is a world built on science. The Society is a global leader in promoting excellence in science education and providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, e-books and weekly news periodical Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a leader in scientific information solutions, its CAS division partners with global innovators to accelerate breakthroughs by curating, connecting and analyzing the world’s scientific knowledge. ACS’ main offices are in Washington, D.C., and Columbus, Ohio.
To automatically receive press releases from the American Chemical Society, contact newsroom@acs.org.
Note to journalists: Please report that this research was presented at a meeting of the American Chemical Society. ACS does not conduct research, but publishes and publicizes peer-reviewed scientific studies.
Follow us: Facebook | LinkedIn | Instagram
Title
Development of a novel GSDMD inhibitor for the treatment of acetaminophen-induced liver injury
Abstract
Acetaminophen overdose can lead to severe liver injury and inflammation that plays a major role in the severity of the injury. Inflammatory proteins, such as NOD-like receptor (NLR) family pyrin domain containing 3 (NLRP3) and gasdermin D (GSDMD) have been shown to play a significant role in acetaminophen-induced liver injury (AILI) and that knocking out or inhibiting these proteins can significantly relieve AILI by reducing an inflammatory form of cell death called pyroptosis in hepatocytes. GSDMD is an essential inflammatory signaling molecule that contributes to pyroptosis through oligomerization of the cleaved N-terminal fragment and the formation of a pore in the cell membrane to release intracellular contents (i.e., inflammatory cytokines such as IL-1β and IL-18). In this study, we developed YM81 as a novel scaffold of GSDMD inhibitor. YM81 is a potent inhibitor of IL-1β release through the NLRP3, NLRC4, and AIM2 inflammasomes (IC50: 950 nM). Biophysical assays also confirmed it as a direct binder of GSDMD (KD: 197.3 ± 36.28 nM). Additionally, YM81 dose-dependently inhibited GSDMD and caspase-1 cleavage in J774A.1 macrophages under LPS/nigericin stimulation. Furthermore, YM81 was also shown to alleviate AILI in mouse models, especially when compared to known inflammasome inhibitor MCC950. Taken together, this data shows that YM81 exhibits significant anti-inflammatory properties through inhibition of GSDMD and that further optimization of the scaffold could lead to even more promising therapeutics for the treatment of inflammatory disorders.
END
WASHINGTON, Aug. 18, 2025 — From electric cars to artificial intelligence (AI) data centers, the technologies people use every day require a growing need for electricity. In theory, nuclear fusion — a process that fuses atoms together, releasing heat to turn generators — could provide vast energy supplies with minimal emissions. But nuclear fusion is an expensive prospect because one of its main fuels is a rare version of hydrogen called tritium. Now, researchers are developing new systems to use nuclear waste ...
A new study published today in Nature Food evaluates the impacts of the European Chicken Commitment (ECC), an initiative calling on food companies to adopt slower-growing breeds and higher welfare standards. While concerns over increased costs and emissions have been barriers to adoption, the study puts those concerns in perspective. For example, using EU carbon externality costs (the cost for companies to emit one tonne of CO₂ under the EU Emissions Trading System), the study showed that it costs less than one-hundredth of a cent to prevent each hour of intense pain —equivalent to the emissions from ...
WASHINGTON, Aug. 18, 2025 — Millions of Americans have altered vision, ranging from blurriness to blindness. But not everyone wants to wear prescription glasses or contact lenses. Accordingly, hundreds of thousands of people undergo corrective eye surgery each year, including LASIK — a laser-assisted surgery that reshapes the cornea and corrects vision. The procedure can result in negative side effects, prompting researchers to take the laser out of LASIK by remodeling the cornea, rather than cutting it, in initial animal tissue tests.
Michael Hill, a professor ...
The trouble with many drugs is that they go where they shouldn’t, producing unwanted side effects. Psychiatric drugs might cause dissociation, painkillers can induce nausea and chemotherapy often damages healthy cells. Now a team of Stanford Medicine researchers are closing in on a novel solution: a non-invasive system that can deliver drugs anywhere in the body with precision down to a few millimeters.
The system uses nanoparticles to encapsulate drugs along with ultrasound to unleash the drugs at their intended destinations.
In a new study, published Aug. 18 ...
The body’s cells change their shape to close gaps such as wounds – with part of the cell flexing depending on the curve of the gap and the organisation of cell-internal structures, a new study reveals.
Epithelial cells line the body’s surfaces inside and out - forming a barrier to protect against physical damage, pathogens, and dehydration. They play key roles in absorbing nutrients and removing waste products, as well as producing substances such as enzymes and hormones.
Scientists have discovered that these cells’ endoplasmic reticulum (ER) ...
High frequency radio waves can wirelessly carry the vast amount of data demanded by emerging technology like virtual reality, but as engineers push into the upper reaches of the radio spectrum, they are hitting walls. Literally.
Ultrahigh frequency bandwidths are easily blocked by objects, so users can lose transmissions walking between rooms or even passing a bookcase. Now, researchers at Princeton engineering have developed a machine-learning system that could allow ultrahigh frequency transmissions to dodge those obstacles. In an August 18 article in Nature Communications, the researchers unveiled a system ...
WASHINGTON, Aug. 18, 2025 — No matter whether it’s crushed or cubed, ice eventually melts into a puddle — but an alternative called jelly ice doesn’t. Researchers Jiahan Zou and Gang Sun developed a one-step process to create the reusable, compostable material from gelatin, the same ingredient in jiggly desserts. Because frozen jelly ice doesn’t leak as it thaws, it’s ideal for food supply chains and medication transport. The team is also exploring protein-based structures for food-safe coatings and lab-grown meat scaffolds.
Zou will present her results at the fall meeting of the American Chemical Society (ACS). ACS Fall ...
What inspired you to become a researcher?
I was introduced to the One Health Initiative during my undergraduate studies, which opened my eyes to the power of collaborative science. This initiative promotes collaboration between veterinary medicine, human medicine, environmental disciplines, and other scientific fields to advance our collective well-being. What fascinated me was how interconnected our health challenges really are – diseases don't respect boundaries between species or environments. I realized that the discoveries we make in ...
Dr. Seon Joon Kim and his team at the Korea Institute of Science and Technology (KIST)'s Convergence Research Center for SEIF have developed a "high-conductivity amphiphilic MXene" material that can be dispersed in water, polar and nonpolar organic solvents. This is an achievement that fundamentally overcomes the solvent compatibility limitation that has hindered the practical use of high-conductivity MXene, and is noted as a general-purpose technology that can be widely applied to high-tech industries in the future.
MXene, a two-dimensional nanomaterial with high electrical conductivity, excellent solvent dispersibility, and excellent EMI shielding ...
The off-label use of ketamine to treat chronic pain is not supported by scientific evidence, a new Cochrane review has found.
Ketamine is an anaesthetic commonly used for procedural sedation and short-term pain relief. Ketamine is also frequently prescribed off-label to manage chronic pain conditions such as nerve pain, fibromyalgia and complex regional pain syndrome. It is one of several NMDA receptor antagonists — a group of drugs thought to reduce pain by blocking certain brain receptors involved in pain signalling.
The review, conducted by researchers from UNSW Sydney , ...
